Business
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
TORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. (" Theralase® "...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive OfficerTORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce that Roger DuMoulin-White, B.Sc., P.Eng., Pro. Dir. has been appointed as President and Chief Executive Officer (\"CEO\") of the Company.Dr. Arkady Mandel, MD, PhD, DSc has tendered his resignation as Interim CEO, but will continue to serve as Chief Scientific Officer (\"CSO\") and as a member of Theralase®'s Board.Mr. DuMoulin-White is the founder of Theralase® and it's former President and CEO. He stepped down as President and CEO in 2018 and has since served in a non-executive business development role.Mr. DuMoulin-White was the subject of a voluntary Settlement Agreement with the Ontario Securities Commission (\"OSC\") dated February 16, 2018 and an OSC Order dated February 26, 2018 which required, among other things, that he resign as a director and officer of Theralase and refrain from holding those positions for a period of five years. That period has expired and Theralase has obtained the approval of the Toronto Stock Venture Exchange (\"TSXV\") to appoint Mr. DuMoulin-White as President and CEO of the Company and to nominate him for election to the Company's Board of Directors at the Company's Annual Meeting on June 29, 2023.Matthew Perraton, PFP, FMA, FCSI, Pro. Dir., Chairman of the Board of Theralase®, stated, \"As Theralase®'s founder and visionary, Roger built the Company from scratch, imparting ideals and a vision that remain the foundation of the Company today. The Board has unanimously agreed that it is in the best interests of Theralase and its shareholders that Roger resume the roles of President and CEO.Mr. Perraton continued, \"We wish to thank Arkady for his dedication and support as the Interim CEO of the Company. Under his leadership, Theralase® has made great strides in our Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study (\"Study II\"), whose strong interim clinical...